Natural Capsules Ltd (NATCAPSUQ) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Natural Capsules Ltd on NSE and BSE, with an AI summary of each filing.
This is with reference to the queries/clarification sought by NSE regarding Point F of Explanatory Statement 1 & 2 in relation to the object of the Preferential Issue.
Others (Uncategorized) · 04 Nov 2026, 6:07 pm
Natural Capsules Clarifies Objects of Preferential Issue for Fund Utilization Natural Capsules Limited issued clarifications on 4th Nov'26 regarding the utilization of proceeds from its preferential issue of equity shares and convertible warrants. The company intends to allocate proceeds of ₹2.00 cr (Item 1) and ₹8.01 cr (Item 2) toward working capital requirements and capital expansion. Working capital allocations will cover raw material procurement, operational costs, employee expenses, and statutory obligations. Capital expansion proceeds will fund plant modernization, manufacturing capacity additions, process automation, and potential acquisition or establishment of an additional unit.
Pursuant to Reg 44(3) of SEBI (LODR) Regulations, 2025 , We are Submitting herewith voting results of 1st Extra-Ordinary General Meeting 2026 of the company held on Wednesday, September 2026
Extra Ordinary General Meeting · 09 Sept 2026, 10:30 pm
Natural Capsules Shareholders Approve Preferential Issues at EGM Natural Capsules Limited announced that shareholders approved two special resolutions at its EGM on 9th Sep'26 with overwhelming majorities. The preferential allotment of equity shares secured 99.99408% approval (3,090,923 votes in favor vs. 183 against). Additionally, the preferential issuance of warrants convertible into equity shares received 99.99337% support (3,090,901 votes in favor vs. 205 against). Total valid votes cast stood at 3,091,106 across both resolutions conducted via remote e-voting.
Pursuant to Regulations 30 of SEBI (LODR) Regulation, 2015 please find the enclosed proceedings of the of 1st Extraordinary General Meeting 2026 of the Company held on Wednesday September ....
Extra Ordinary General Meeting · 09 Sept 2026, 10:26 pm
Natural Capsules Transacts Preferential Issue Resolutions at Extraordinary General Meeting Natural Capsules Limited conducted its 1st Extraordinary General Meeting on 9th Sep'26 via video conferencing to seek shareholder approval for key capital-raising proposals. Shareholders deliberated on two special resolutions: the preferential allotment of equity shares and the issuance of convertible warrants into equity shares on a preferential basis. Remote e-voting was held from 4th Sep'26 to 8th Sep'26 alongside e-voting during the meeting. Final voting results will be declared separately following the submission of the Scrutinizer's report.
We wish to inform you that the company has today, Wednesday, September 02, 2026, completed the dispatch of the Corrigendum to the EGM Notice to all eligible members of the Company.
Extra Ordinary General Meeting · 02 Sept 2026, 11:35 pm
Natural Capsules Revises Preferential Allotment Terms to ₹178 Per Share and Warrant Natural Capsules issued a corrigendum for its 9th Sep'26 EGM, revising terms for a preferential allotment to promoter Sunil Laxminarayan Mundra. The company will issue up to 1,12,500 equity shares and 4,50,000 convertible warrants at a revised price of ₹178 each. The combined ₹10.01 crore proceeds will primarily fund working capital requirements and capital expansion. Post-issue and upon full warrant conversion, Mundra's stake will increase from 5.79% to 10.61%.
Natural Capsules Limited has informed the Exchange regarding Outcome of Board Meeting held on September 02, 2026.
Outcome · 02 Sept 2026, 4:55 pm
1. Approved the Revised Price and Quantity of Equity Shares and Convertible Warrants of Preferential Issue. 2. Approval of the Corrigendum Notice of Extra Ordinary General Meeting.
Outcome · 02 Sept 2026, 4:48 pm
NATURAL CAPSULES LIMITED has informed the Exchange about Board Meeting to be held on 02-Sep-2026 to consider and approve Fund raising/Other business.
Intimation · 02 Sept 2026, 12:09 am
Natural Capsules Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/09/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 ....
Intimation · 02 Sept 2026, 5:30 am
Natural Capsules Board to Revise Preferential Issue Terms Natural Capsules (NATCAPSUQ) will hold a board meeting on 02 Sep'26 on shorter notice to discuss a proposed preferential issue. The agenda includes considering an updated valuation report requested by BSE & NSE. Following this, the board will evaluate and approve a revised issue price, quantity of equity shares, and warrants for the preferential allotment. The meeting is being held urgently to respond to exchange queries and revise the allotment price within statutory timelines, impacting potential capital raising and shareholder dilution.
Cut-off Date (Record Date) for Extraordinary General Meeting ("EGM") is fixed on September 2nd, 2026.
Others · 18 Aug 2026, 8:07 pm
Natural Capsules Sets Record Date for Upcoming EGM Natural Capsules Limited has scheduled an Extraordinary General Meeting (EGM) for Sep 09, '26. The company has fixed Sep 02, '26 as the cut-off date (record date) for the purpose of the EGM. This information was communicated to the BSE (Scrip: 524654) and NSE (Symbol: NATCAPSUQ) on Aug 18, '26.
We are hereby submitting the Notice of the Extraordinary General Meeting (EGM) of the Company scheduled to be held on Wednesday, September 09, 2026 at 12:00 PM (IST) through Video Conference ....
Extra Ordinary General Meeting · 18 Aug 2026, 7:34 pm
Natural Capsules to Raise ₹10 Crore via Preferential Allotment to Promoters Natural Capsules will hold an EGM on 09 Sep'26 to approve a preferential allotment to promoter Mr. Sunil Laxminarayan Mundra. The company plans to raise ₹10 crore by issuing 1,25,000 equity shares and 5,00,000 convertible warrants, both priced at ₹160 per security. This comprises a ₹2 crore share issue and an ₹8 crore warrant issue. Funds will be used for working capital and capital expansion. Post-allotment, the total promoter group holding will increase from 50.92% to 53.70% on a fully diluted basis.
This is to inform you that Mr. Pramod Kasat has tendered his resignation from the position of Independent Director of Natural Biogenex Private Limited ("Material Unlisted Subsidiary"), ....
Others (Uncategorized) · 18 Aug 2026, 12:21 am
Natural Capsules: Director Resigns From Material Subsidiary Mr. Pramod Kasat has resigned from his position as an Independent Director of Natural Biogenex Private Limited, a material unlisted subsidiary of Natural Capsules Ltd. The resignation is effective from 17 Aug'26 and is attributed to professional commitments. This change in key management personnel at a material subsidiary level is a notable governance event for the parent company. The company has confirmed there are no other material relationships to disclose.
Approved the Unaudited Consolidated & Standalone Financial Results of the Company for the Quarter ended June 30, 2026.
Financial Result · 16 Aug 2026, 8:28 pm
Natural Capsules Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakhs) ■ Revenue: 4,871 (+7.8% YoY | -16.7% QoQ) ■ EBITDA: 112 (+250.8% YoY | -15.8% QoQ) ■ EBITDA Margin (%): 2.3 (+159 bps YoY | +2 bps QoQ) ■ PAT: -398 (+28.7% YoY | -15.4% QoQ) ■ EPS (INR): -5.54 (-2.6% YoY | -15.4% QoQ) Natural Capsules Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakhs) Segmental Performance Capsules ■ Revenue: 4,302 (-2.8% YoY | -15.3% QoQ) ■ EBIT: 710 (+46.9% YoY | -20.4% QoQ) ■ EBIT Margin (%): 16.5 (+558 bps YoY | -105 bps QoQ) API ■ Revenue: 569 (+492.7% YoY | -25.6% QoQ) ■ EBIT: -804 (-15.1% YoY | +14.0% QoQ) ■ EBIT Margin (%): -141 (+58621 bps YoY | -1915 bps QoQ)
We are submitting herewith voting results & scrutinizers report of 33rd AGM of Natural Capsules Limited.
Annual General Meeting · 13 Aug 2026, 5:40 pm
Please find enclosed herewith the copy of Investors Presentation in connection with the Unaudited Consolidated & Standalone Financial Results for quarter ended June 30, 2026.
Investor Presentation · 13 Aug 2026, 6:31 am
Natural Capsules Q1FY27 Results: Strong EBITDA Growth, Revenue Decline QoQ For Q1FY27 ending 30 Jun'26, Natural Capsules reported consolidated revenues of ₹48.71 Cr, down 17% QoQ but up 8% YoY. EBITDA stood at ₹1.12 Cr, declining 16% QoQ while surging 251% YoY. EBITDA margins expanded 159 bps YoY to 2.30%. The company posted a net loss (PAT) of ₹5.74 Cr. Management noted strong underlying performance in the capsules business, with reported revenue impacted by a brief ERP implementation disruption. The company is temporarily converting HPMC lines to gelatine lines to optimize capacity amid US market uncertainty.
Please find enclosed herewith the copy of Press Release made to analysts and investors in connection with the Unaudited Consolidated & Standalone Financial Results for quarter ended June 30, 2026.
Press Release · 13 Aug 2026, 6:19 am
Natural Capsules Q1FY27: Strong YoY Growth Despite QoQ Dip Natural Capsules reported Q1FY27 revenue of ₹48.71 Cr (-17% QoQ, +8% YoY) and PAT of ₹5.74 Cr (-15% QoQ, +3% YoY). The QoQ decline is due to a high base from deferred inventory dispatch in Q4FY26. EBITDA margin expanded 159 bps YoY to 2.30%, driven by input cost pass-throughs and rupee depreciation. An ERP disruption pushed some sales from Jun'26 into Q2FY27. While US HPMC demand remains erratic, the company initiated its first contract manufacturing batch with Fermbox Bio in Aug'26.
Natural Biogenex Private Limited ("Material Unlisted Subsidiary"), at its Board Meeting held on today has appointed Mr. K. H. Honneshaiah as the new Chief Operating Officer of the Company.
Others (Uncategorized) · 13 Aug 2026, 1:15 am
Natural Capsules Appoints New COO for Material Subsidiary Natural Capsules announced on 12 Aug'26 the appointment of Mr. K. H. Honneshaiah as the new Chief Operating Officer (COO) for its material unlisted subsidiary, Natural Biogenex Private Limited. Mr. Honneshaiah brings 36 years of operations and manufacturing leadership experience in regulated API, specialty chemicals, polymers, and peptides. His expertise includes scaling pharma plants, building greenfield capacity, and driving profitable growth, indicating a strategic focus on strengthening operational leadership within the key subsidiary.
1. Approved the unaudited Consolidated & Standalone Financial Results of the Company for the Quarter ended June 30, 2026. 2. Preferential Issue of Equity Shares and Warrants to Promoter.
Outcome · 12 Aug 2026, 11:55 pm
Natural Capsules Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 4,871 (+7.8% YoY | -16.7% QoQ) ■ EBITDA: 112 (+250.8% YoY | -15.8% QoQ) ■ EBITDA Margin (%): 2.3 (+159 bps YoY | +2 bps QoQ) ■ PAT: -398 (+28.7% YoY | -15.4% QoQ) ■ EPS (INR): -5.54 (-2.6% YoY | -15.4% QoQ) Natural Capsules Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) Segmental Performance Capsules ■ Revenue: 4,302 (-2.8% YoY | -15.3% QoQ) ■ EBIT: 710 (+46.9% YoY | -20.4% QoQ) ■ EBIT Margin (%): 16.5 (+558 bps YoY | -105 bps QoQ) API ■ Revenue: 569 (+492.7% YoY | -25.6% QoQ) ■ EBIT: -804 (-15.1% YoY | +14.0% QoQ) ■ EBIT Margin (%): -141 (+58621 bps YoY | -1915 bps QoQ)
33rd Annual General Meeting of the Company held on Wednesday August 12, 2026 at 12.10 P.M. through Video conferencing ("VC") other Audio-visual Means ("OAVM") and was concluded at 01:00 PM.
Annual General Meeting · 12 Aug 2026, 11:03 pm
Natural Capsules Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve Update on board meeting 1. ....
Intimation · 12 Aug 2026, 5:30 am
Natural Capsules Board to Consider Fundraising via Preferential Issue Natural Capsules' Board will consider a proposal for fundraising at its meeting on 12 Aug'26. The plan involves issuing equity shares, convertibles, or other eligible securities on a preferential basis, subject to regulatory and shareholder approvals. This is in addition to the previously announced agenda item of approving the unaudited financial results for the quarter ended 30 Jun'26. The trading window for designated persons has been closed since 01 Jul'26 and will reopen 48 hours after the results are declared.
Natural Capsules Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve 1. To Consider and approve ....
Intimation · 12 Aug 2026, 5:30 am
Natural Capsules Board Meeting Set for Aug 12, '26 to Approve Q1 Results Natural Capsules Ltd (NATCAPSUQ) will hold a Board of Directors meeting on 12th Aug'26. The primary agenda is to consider and approve the unaudited standalone and consolidated financial results for the quarter ended 30th Jun'26. In compliance with SEBI insider trading regulations, the trading window for designated persons has been closed since 01st Jul'26 and will reopen 48 hours after the results are declared.
Natural Biogenex Private Limited ("Material Unlisted Subsidiary"), at its Board Meeting held on today, i.e. July 31, 2026, has approved the Allotment of the Right Issue duly approved on ....
Others (Uncategorized) · 31 Jul 2026, 11:14 pm
Natural Capsules' Subsidiary Approves Rights Issue Allotment Natural Capsules Limited announced that its material unlisted subsidiary, Natural Biogenex Private Limited, approved the allotment of a rights issue on 31 Jul'26. The allotment comprises 9,46,305 equity shares with a face value of ₹10 each, issued at par for cash. This aggregates to a total capital infusion of ₹94,63,050. The initial rights issue was approved by the board on 10 Jul'26. This move will enhance the subsidiary's capital base.
Board of Director of the Company has inter-alia considered and approved a Resolution Passed by Circulation on 28th July, 2026 and the final majority vote was received by 08:00 PM decided ....
Rights Issue · 30 Jul 2026, 12:32 am
Natural Capsules' Holding in Subsidiary Diluted by 2.18% Post Rights Issue Natural Capsules announced on 29 Jul'26 that its equity stake in subsidiary Natural Biogenex Private Limited has been diluted by 2.18%. The dilution occurred after the Board decided on 28 Jul'26 not to participate in the subsidiary's rights issue. Consequently, the company's shareholding decreased from 68.96% to 66.78% of the revised paid-up capital. The non-participation was cited as a strategic allocation of funds to other business matters. The subsidiary remains a subsidiary of the company post-dilution.
Annual Report for the Financial Year 2025-26.
Others (Uncategorized) · 18 Jul 2026, 3:35 am
Notice of the 33rd Annual General Meeting ("AGM") of the Company scheduled to be held on Wednesday, August 12, 2026, at 12:00 PM (IST) through Video Conference ("VC") or Other Audio Visual ....
Annual General Meeting · 17 Jul 2026, 11:14 pm
The Record Date for 33rd Annual General Meeting is set on August 05, 2026; Wednesday.
Others · 17 Jul 2026, 7:28 pm